Skip to main content

Table 2 Characteristics of nr-axSpA patients at initiation of first TNFi treatment after exclusion of patients with co-morbid fibromyalgia

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Parameter N, 163 Men, N = 78 Women, N = 85 p
Age, years 163 35.6 (10.8) 39.1 (11.4) 0.10
Age at onset, years 162 27.9 (8.6) 28.1 (8.5) 0.66
Symptom duration, years 163 7.6 (8.8) 10.9 (10.8) 0.05
Diagnostic delay, years 162 4.1 (7.6) 7.8 (9.9) 0.005
HLA-B27 positive, % 149 75.7 68.0 0.36
Prior sacroiliitis on MRI, % 154 70.8 68.3 0.86
BASDAI 148 5.3 (2.0) 6.3 (1.6) 0.003
Physician Global Assessment 155 5.0 (1.9) 4.8 (1.6) 0.63
Patient Global Assessment 149 6.4 (2.2) 6.7 (2.1) 0.30
ASDAS 140 3.3 (1.0) 3.4 (0.7) 0.29
ASDAS > 2.1, % 140 83.9 96.2 0.02
CRP (mg/l), median (IQR) 154 6.0 (2.0; 12.0) 5.0 (3.0; 9.0) 0.43
Elevated CRP, % 154 42.5 38.3 0.62
BASFI 148 3.6 (2.4) 3.8 (2.5) 0.54
BASMI 141 1.2 (1.1) 1.4 (1.2) 0.42
EQ-5D 141 54.8 (22.8) 55.8 (18.3) 0.79
Current periph. Arthritis,% 159 41.6 52.4 0.20
Number of swollen joints 155 0.7 (1.2) 1.3 (2.5) 0.32
Current enthesitis, % 158 80.5 85.2 0.53
Modified MASES 157 2.3 (2.5) 3.9 (3.3) 0.002
Dactylitis ever, % 161 13.2 21.2 0.21
csDMARDs ever, % 163 26.9 41.2 0.07
Taking NSAIDs, % 150 92.9 86.2 0.29
Current smoking, % 139 28.3 22.8 0.55
Body mass index 160 25.9 (4.2) 24.0 (4.4) < 0.001
Type of TNFi, % 163    0.25
• Adalimumab   34.6 45.9  
• Certolizumab   1.3 0.0  
• Etanercept   19.2 15.3  
• Golimumab   20.5 24.7  
• Infliximab   24.4 14.1  
  1. Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. Patients with co-morbid fibromyalgia were excluded from these analyses. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein levels; csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, EQ-5D EuroQol 5-domains, HLA-B27 human leucocyte antigen B27, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor